United States - English - NLM (National Library of Medicine)

neogen corporation - trimethoprim (unii: an164j8y0x) (trimethoprim - unii:an164j8y0x), sulfadiazine (unii: 0n7609k889) (sulfadiazine - unii:0n7609k889) - trimethoprim 67 mg in 1 g - uniprim powder for horses is indicated in horses where potent systemic antibacterial action against sensitive organisms is required. uniprim powder for horses is indicated where control of bacterial infections is required during treatment of: uniprim powder for horses is well tolerated by foals. trimethoprim and sulfadiazine should not be used in horses showing marked liver parenchymal damage, blood dyscrasias, or in those with history of sulfonamide sensitivity.

United States - English - NLM (National Library of Medicine)

neogen corporation - trimethoprim (unii: an164j8y0x) (trimethoprim - unii:an164j8y0x), sulfadiazine (unii: 0n7609k889) (sulfadiazine - unii:0n7609k889) - uniprim powder for horses is indicated in horses where potent systemic antibacterial action against sensitive organisms is required. uniprim powder for horses is indicated where control of bacterial infections is required during treatment of: uniprim powder for horses is well tolerated by foals. trimethoprim and sulfadiazine should not be used in horses showing marked liver parenchymal damage, blood dyscrasias, or in those with history of sulfonamide sensitivity.

United States - English - NLM (National Library of Medicine)

pfizer laboratories div pfizer inc - prazosin hydrochloride (unii: x0z7454b90) (prazosin - unii:xm03yj541d) - prazosin 1 mg - minipress is indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program's joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (jnc). numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanis

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - prazosin hydrochloride, quantity: 5.476 mg (equivalent: prazosin, qty 5 mg) - tablet, uncoated - excipient ingredients: calcium hydrogen phosphate; microcrystalline cellulose; magnesium stearate; sodium lauryl sulfate; maize starch - indications as at 31 april 2004: in patients with hypertension. minipress (prazosin hydrochloride) is indicated in the treatment of hypertension of varied aetiology and all grades of severity. it can be used as the initial and sole agent or it may be employed in a treatment programme in conjunction with other antihypertensive agents. renal blood flow and glomerular filtration rate are not impaired by long-term oral administration. minipress can be used with safety in hypertensive patients with impaired renal function. in patients with congestive heart failure. minipress is indicated in the treatment of severe refractory congestive heart failure. minipress may be added to the therapeutic regime in those patients who have become refractory to conventional therapy with cardiac glycosides and diuretics. in patients with raynaud's phenomenon and raynaud's disease. minipress is indicated in the treatment of raynaud's phenomenon and raynaud's disease. benign prostatic hyperplasia. minipress is indicated as an adjunc

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - prazosin hydrochloride, quantity: 2.19 mg (equivalent: prazosin, qty 2 mg) - tablet, uncoated - excipient ingredients: calcium hydrogen phosphate; microcrystalline cellulose; magnesium stearate; sodium lauryl sulfate; maize starch - indications as at 30 april 2004: in patients with hypertension. minipress (prazosin hydrochloride) is indicated in the treatment of hypertension of varied aetiology and all grades of severity. it can be used as the initial and sole agent or it may be employed in a treatment programme in conjunction with other antihypertensive agents. renal blood flow and glomerular filtration rate are not impaired by long-term oral administration. minipress can be used with safety in hypertensive patients with impaired renal function. in patients with congestive heart failure. minipress is indicated in the treatment of severe refractory congestive heart failure. minipress may be added to the therapeutic regime in those patients who have become refractory to conventional therapy with cardiac glycosides and diuretics. in patients with raynaud's phenomenon and raynaud's disease. minipress is indicated in the treatment of raynaud's phenomenon and raynaud's disease. benign prostatic hyperplasia. minipress is indicated as an adjunc

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - prazosin hydrochloride, quantity: 1.095 mg (equivalent: prazosin, qty 1 mg) - tablet, uncoated - excipient ingredients: calcium hydrogen phosphate; microcrystalline cellulose; magnesium stearate; sodium lauryl sulfate; sunset yellow fcf; maize starch - indications as at 30 april 2004: in patients with hypertension. minipress (prazosin hydrochloride) is indicated in the treatment of hypertension of varied aetiology and all grades of severity. it can be used as the initial and sole agent or it may be employed in a treatment programme in conjunction with other antihypertensive agents. renal blood flow and glomerular filtration rate are not impaired by long-term oral administration. minipress can be used with safety in hypertensive patients with impaired renal function. in patients with congestive heart failure. minipress is indicated in the treatment of severe refractory congestive heart failure. minipress may be added to the therapeutic regime in those patients who have become refractory to conventional therapy with cardiac glycosides and diuretics. in patients with raynaud's phenomenon and raynaud's disease. minipress is indicated in the treatment of raynaud's phenomenon and raynaud's disease. benign prostatic hyperplasia. minipress is indicated as an adjunc

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - prazosin hydrochloride -

Malta - English - Medicines Authority

recordati ireland limited raheens east, ringaskiddy co. cork, ireland - enalapril maleate, lercanidipine hydrochloride - film-coated tablet - enalapril maleate 10 mg lercanidipine hydrochloride 10 mg - agents acting on the renin-angiotensin system

Malta - English - Medicines Authority

recordati ireland limited raheens east, ringaskiddy co. cork, ireland - enalapril maleate, lercanidipine hydrochloride - film-coated tablet - enalapril maleate 20 mg lercanidipine hydrochloride 10 mg - agents acting on the renin-angiotensin system

Malta - English - Medicines Authority

recordati ireland limited raheens east, ringaskiddy co. cork, ireland - enalapril maleate, lercanidipine hydrochloride - film-coated tablet - enalapril maleate 20 mg lercanidipine hydrochloride 20 mg - agents acting on the renin-angiotensin system